Panhematin (hemin)
Antiporphyria Factors Intravenous Vial (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This medication is used to treat the symptoms that occur with certain blood disorders (porphyrias). Hemin is not a cure for porphyria. This medication may relieve symptoms such as pain, high blood pressure, rapid heartbeat, or mental changes that may occur during an acute attack of porphyria.
Generic name: hemin
Pronunciation: (HEE-min)
Drug class: Antiporphyria Factors
Therapeutic class: Hematological Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Panhematin
Indications
The following indications are listed for Panhematin:
- Acute Intermittent Porphyria
- Hereditary Coproporphyria
- Variegate Porphyria
Also known as: Acute Porphyria, Mixed Porphyria, Porphyria Variegata, Protocoproporphyria, Protocoproporphyria Hereditaria, Pyrroloporphyria, South African Genetic Porphyria, South African Type Porphyria, Swedish Porphyria.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Panhematin 350 Mg Vial | Maintenance | Infuse 3 mg/kg over at least 30 minute(s) by intravenous route once daily. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Hemin/Anticoagulants
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Mild, transient anticoagulant effects has been reported with the use of hemin.(1)
CLINICAL EFFECTS: Concurrent use of hemin with anticoagulants may increase the risk of bleeding.(1)
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: The manufacturer of hemin states concurrent use with anticoagulant therapy should be avoided.(1) If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory tests (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: Mild, transient anticoagulant effects have been reported during clinical studies with hemin.(1)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
- Increased risk of bleeding due to coagulation disorder
- Phlebitis
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Anaphylaxis
- Chronic iron overload
- Hemolysis
- Hypersensitivity drug reaction
- Increased risk of bleeding due to coagulation disorder
- Thrombocytopenic disorder
- Thrombotic disorder
More Frequent
- Fever
- Headache disorder
- Injection site sequelae
- Phlebitis after infusion
Rare or Very Rare
- Cellulitis
- Erythema
- Skin rash
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Acute intermittent porphyria | ||
| E80.21 | ICD10CM | Acute intermittent (hepatic) porphyria |
| Hereditary coproporphyria | ||
| E80.29 | ICD10CM | Other porphyria |
| Variegate porphyria | ||
| E80.20 | ICD10CM | Unspecified porphyria |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.